Table 3.
Calculated pharmacokinetic parameters of TSIIA following IP administration of tested LNC Formulations and TSIIA suspension (5 mg/kg) to healthy rats
| TSIIA suspension | TSIIA-LNCs | TSIIA-PS-LNCs | TSIIA-HA-LNCs | |
|---|---|---|---|---|
| t½ (h) | 8.6±0.9b | 11.4 ab±0.4 | 12 ab±1.9 | 13.4 a±0.5 |
| Tmax (h) | 1±0 | 1±0 | 1±0 | 1±0 |
| Cmax (ng/mL) | 50.8 b±5.7 | 142.8 a±19.9 | 137.2 a±18.4 | 133.8 a±10.3 |
| AUC0–72 (ng/mL*h) | 428.4 b±21.1 | 1,027.2 a±83.1 | 1,076.9 a±73.7 | 958 a±4.5 |
| AUC0–∞ (ng/mL*h) | 436.3 b±23.9 | 1,045.3 a±86.6 | 1,115.5 a±56.4 | 976 a±6.9 |
| MRT (h) | 10.3 c±0.2 | 14.1 b±0.7 | 16.9 a±0.6 | 14.8 ab±0.6 |
| Relative bioavailability# | — | 2.4 | 2.5 | 2.2 |
Notes: The study was done on Wistar rats with seven animals in each group. Values expressed as means ± SEM. Data analyzed using one-way ANOVA followed by post hoc Tukey’s test for pairwise comparisons. Means of similar symbols are statistically insignificant: a > b > c (p≤0.01). #Relative bioavailability was calculated as a ratio of AUC0–72 for all LNC formulations to TSIIA suspension.